Step 1 of 2
TROP2-directed antibody–drug conjugates (ADCs) are expanding treatment options for patients with advanced non-small-cell lung cancer (NSCLC), bringing new considerations for treatment selection, sequencing, and toxicity management. In this downloadable teaching resource, you will find expert-led information on the current and evolving role of TROP2-directed ADCs in NSCLC. Topics covered include treatment of EGFR-mutated disease, emerging clinical trial evidence for ADC combinations, biomarker-driven approaches, and multidisciplinary strategies to prevent, recognize, and manage key adverse events.